Literature DB >> 6291785

Continuing kappa-gene rearrangement in a cell line transformed by Abelson murine leukemia virus.

S Lewis, N Rosenberg, F Alt, D Baltimore.   

Abstract

A cell line transformed by Abelson murine leukemia virus, called PD, is capable of carrying out kappa-gene rearrangement while growing in culture. Subclones of PD have diverse kappa-gene structures, and some derivatives show evidence of continued joining activity after as many as three subclonings. Analysis of PD sublineages has shown that a rearranged chromosome can undergo secondary kappa-gene rearrangements, producing either a new rearrangement or a deletion of C kappa. Although the PD line actively rearranges its kappa genes, its rearranged heavy-chain genes show little variation, and there is no rearrangement of lambda genes. In PD subclones, DNA fragments representing the reciprocal product of kappa-gene rearrangement are often evident, and they may undergo either further rearrangement or deletion. The implications of multiple rearrangements on a single chromosome and of the maintenance of reciprocal fragments are considered in the context of a model that postulates that the V kappa and J kappa segments are not all organized in the DNA in the same transcriptional direction, leading to inversions rather than deletions during joining.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6291785     DOI: 10.1016/0092-8674(82)90285-9

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  104 in total

1.  Concanavalin A stimulation enhanced secondary VlambdaJlambda rearrangement in some human plasma B cells without up-regulation of recombination-activating gene expression and Vlambda germline transcription.

Authors:  H Haruta; H Tachibana; K Yamada
Journal:  Immunology       Date:  1999-08       Impact factor: 7.397

Review 2.  Receptor selection in B and T lymphocytes.

Authors:  D Nemazee
Journal:  Annu Rev Immunol       Date:  2000       Impact factor: 28.527

3.  Complex regulation of the immunoglobulin mu heavy-chain gene enhancer: microB, a new determinant of enhancer function.

Authors:  B Nelsen; T Kadesch; R Sen
Journal:  Mol Cell Biol       Date:  1990-06       Impact factor: 4.272

4.  Interaction of a nuclear protein with a palindromic sequence of the mouse immunoglobulin lambda 2-chain gene promoter is important for its transcription.

Authors:  L A Chang; H Murialdo
Journal:  Mol Cell Biol       Date:  1990-11       Impact factor: 4.272

5.  Targeted disruption of the porcine immunoglobulin kappa light chain locus.

Authors:  J Ramsoondar; M Mendicino; C Phelps; T Vaught; S Ball; J Monahan; S Chen; A Dandro; J Boone; P Jobst; A Vance; N Wertz; I Polejaeva; J Butler; Y Dai; D Ayares; K Wells
Journal:  Transgenic Res       Date:  2010-09-26       Impact factor: 2.788

6.  Cryoglobulinemia induced by a murine IgG3 rheumatoid factor: skin vasculitis and glomerulonephritis arise from distinct pathogenic mechanisms.

Authors:  L Reininger; T Berney; T Shibata; F Spertini; R Merino; S Izui
Journal:  Proc Natl Acad Sci U S A       Date:  1990-12       Impact factor: 11.205

7.  A poly(dA-dT) upstream activating sequence binds high-mobility group I protein and contributes to lymphotoxin (tumor necrosis factor-beta) gene regulation.

Authors:  S J Fashena; R Reeves; N H Ruddle
Journal:  Mol Cell Biol       Date:  1992-02       Impact factor: 4.272

8.  Regulation and a possible stage-specific function of Oct-2 during pre-B-cell differentiation.

Authors:  C L Miller; A L Feldhaus; J W Rooney; L D Rhodes; C H Sibley; H Singh
Journal:  Mol Cell Biol       Date:  1991-10       Impact factor: 4.272

9.  Involvement of wild-type p53 in pre-B-cell differentiation in vitro.

Authors:  G Shaulsky; N Goldfinger; A Peled; V Rotter
Journal:  Proc Natl Acad Sci U S A       Date:  1991-10-15       Impact factor: 11.205

10.  Mouse mammary tumor virus superantigen expression in B cells is regulated by a central enhancer within the pol gene.

Authors:  F U Reuss; J M Coffin
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.